✦ LIBER ✦

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

✍ Scribed by Scheen, André J

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

GLP-1 agonists for type 2 diabetes: phar

✍ Jespersen, Maria J; Knop, Filip K; Christensen, Mikkel 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 281 KB

Canagliflozin: SGLT2 inhibitor for treat

✍ Donnelly, Richard 📂 Article 📅 2013 🏛 Wiley (John Wiley & Sons) ⚖ 229 KB

SGLT2 versus DPP4 inhibitors for type 2

✍ Scheen, André J 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 53 KB

Canagliflozin, a Novel SGLT2 Inhibitor f

✍ Nigro, S. C.; Riche, D. M.; Pheng, M.; Baker, W. L. 📂 Article 📅 2013 🏛 Harvey Whitney Books Company 🌐 English ⚖ 365 KB

SGLT2 inhibitors: a promising new therap

✍ Monika Misra 📂 Article 📅 2012 🏛 Pharmaceutical Press 🌐 English ⚖ 337 KB

Efficacy and Safety of SGLT2 Inhibitors

✍ Muhammad A. Abdul-Ghani; Luke Norton; Ralph A. DeFronzo 📂 Article 📅 2012 🏛 Current Science Inc. 🌐 English ⚖ 224 KB